Eikon Therapeutics, Inc. (EIKN) Posts 63% ORR in NSCLC Combo Trial

Eikon Therapeutics (EIKN) reported 63.1% ORR in NSCLC combo trial with EIK1001, pembrolizumab, and chemo. Squamous cohort showed 72.4% ORR, 100% DCR, and 12.9-month median DOR. Phase 2/3 trial ongoing, with interim analysis expected in 2H 2027. Safety profile was consistent with standard of care.

Original reporting
Published Oct 26, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Eikon Therapeutics, Inc. (EIKN) Posts 63% ORR in NSCLC Combo Trial — source image
Decision brief

The 30-second read

$EIKNBullishMed
01

Why it matters

The disclosed ORR and DCR exceed historical benchmarks, potentially accelerating the company's path to market.

02

Market read

The trial data is a catalyst for EIKN and may influence peer oncology stocks.

03

What to watch

Regulatory review timelines and competitive landscape in NSCLC therapies.

Relevance 9/10Novelty 8/10Timing: today

Background

Eikon Therapeutics is developing TLR7/8 agonist EIK1001 combined with pembrolizumab and chemotherapy for first‑line NSCLC.

Company-level read

Ticker impact

$EIKNBullishHigh confidence
Context

Eikon Therapeutics reported a 63.1% ORR and 89.2% DCR in its Phase 2/3 NSCLC combo trial, the first public disclosure of these results.

Expected impact

likely upward pressure as the market prices in the positive trial data

Evidence & confidence

Phase 2/3 data with high response rates is material for a biotech and often triggers price appreciation.

Market effects

Positive NSCLC data could boost the broader oncology biotech sector.

US biotech market may see modest gains.

Limited to investors tracking cancer therapeutics pipelines.

Counterpoint

If the data does not translate into survival benefit, the rally could be short-lived.

Key entities

  • Eikon Therapeutics, Inc.

    Biotech firm reporting trial results.

Related articles

$EIKNMedAI 8/10

Eikon gets FDA clearance for prostate cancer drug trial

Eikon Therapeutics (EIKN) received FDA clearance for its prostate cancer drug EIK1006, advancing to Phase 1/2 trials. The study, ARGATE-001, will assess safety and efficacy in metastatic prostate cancer patients resistant to standard therapies. Dosing is expected to start in 2027, with preliminary data by late 2027. EIK1006 targets androgen receptor pathway alterations, a common cause of treatment resistance.

$EIKNMedAI 8/10

Eikon Therapeutics Reports $86.1 Million Q3 Net Loss, $461.7 Million in Cash

Eikon Therapeutics reported a Q3 2026 net loss of $86.1M, up from $71.1M a year earlier. Cash reserves totaled $461.7M. R&D expenses rose to $71.8M. The company reported clinical progress in its oncology pipeline, including NSCLC and prostate cancer trials. EIK1001 showed a 63.1% response rate in NSCLC. Eikon plans to initiate a Phase 1/2 study for EIK1006, pending FDA clearance.

$EIKNMedAI 8/10

Eikon Therapeutics Reports Third Quarter 2026 Financial Results

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates • Presented seven posters at the 2026 European Society for Medical Oncology (ESMO) Congress highlighting progress across the oncology portfolio, including clinical data from

$EIKNMedAI 8/10

Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029

Eikon Therapeutics (NASDAQ:EIKN) reported progress in its melanoma trial, expecting key data in 2029. The company also discussed its PARP1 inhibitors, EIK1003 and EIK1004, showing promising early results in combination therapies. Eikon's pipeline includes a Werner helicase inhibitor and an androgen receptor antagonist, with patient enrollment expected soon for the latter. The company aims to leverage its live-cell imaging technology for drug discovery in oncology and other serious diseases.